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Key Clinical Message
Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy,
Skin changes (POEMS) syndrome is a rare plasma cell disorder that causes a
paraneoplastic syndrome. We report the first case of POEMS syndrome with
synchronous breast cancer. The patient was at risk of being misdiagnosed with
metastatic cancer, and it is important to emphasize that physical examinations
provided vital diagnostic clues.
Keywords
Breast cancer, differential diagnosis, POEMS syndrome.
Introduction
Polyneuropathy, Organomegaly, Endocrinopathy, Mono-
clonal gammopathy, Skin changes (POEMS) syndrome
causes the following clinical manifestations: (the initial
letters of which form the word POEMS) as well as
extravascular volume overload, erythrocytosis/thrombo-
cytosis, osteosclerotic lesions, and elevated vascular
endothelial growth factor (VEGF) levels [1]. Table 1
shows the diagnostic criteria for POEMS syndrome.
The condition is diagnosed based on the presence of
both polyradiculoneuropathy and a monoclonal plasma
cell disorder, as well as at least one of the other three
major criteria and at least one minor criterion. POEMS
syndrome is often misdiagnosed because its symptoms
mimic those of other disorders. In addition, it has a
rapidly progressive course; therefore, early diagnosis is
important. Pleural effusion, ascites, and/or cardiac effu-
sion are the first symptoms to appear in more
than half of patients with POEMS syndrome, and
these conditions can become life-threatening in some
cases [2].
Due to the abovementioned unique manifestations of
POEMS syndrome, it can be difficult to achieve an early
or accurate diagnosis in cases in which a patient with
undiagnosed POEMS syndrome develops cancer. In other
words, pleural effusion, ascites, lymphadenopathy, and
bone lesions caused by POEMS syndrome might be mis-
diagnosed as cancer metastases if the preexisting POEMS
syndrome is not detected. Herein, we present the first
case report of POEMS syndrome with synchronous breast
cancer and describe potential diagnostic problems associ-
ated with such cases.
Case history/examination
A 65-year-old female with a chief complaint of coxalgia,
which had lasted for 2 years, presented to a nearby hospi-
tal. A computed tomography (CT) scan showed multiple
sclerotic bone lesions, which were suggestive of an occult
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primary tumor and multiple bone metastases. Despite
extensive testing for 3 months, no final diagnosis was
made so the patient was referred to our hospital for a sec-
ond opinion. By that time, she had developed further
symptoms; that is, a prolonged bloating sensation and
visible abdominal distension, which had lasted for a
month. She received a thorough examination at our hos-
pital’s internal medicine department, including various
blood tests; imaging examinations, such as CT and mam-
mography; upper and lower endoscopy; and cytoscreening
(a biochemical examination) of her ascites. The differen-
tial diagnosis process particularly focused on autoimmune
connective tissue disorders in addition to a further exami-
nation for occult primary cancer. The patient’s laboratory
data were indicative of anemia, thrombocytopenia, low
serum albumin levels, kidney dysfunction, and subclinical
hypothyroidism, but no autoantibodies associated with
autoimmune connective tissue disorders were detected
(Table 2A–B). A CT scan showed a small to moderate
amount of pleural effusion, a large amount of ascites,
enlargement of both axillary lymph nodes, and multiple
sclerotic bone lesions, but did not detect any tumors of
the parenchymal organs or lymphadenopathy (Fig. 1A–
C). Diagnostic aspiration indicated that the patient’s
ascites (Table 3) was transudative, but not malignant. A
right-sided mammography showed a cluster of pleomor-
phic microcalcifications (Fig. 2A). In agreement with this
lesion, a breast ultrasound scan detected a hypoechoic
solid tumor (size: ~1 cm) containing internal echogenic
spots with interruption of both the anterior and posterior
borders of the mammary gland (Fig. 2B). Therefore, an
ultrasound-guided needle biopsy was performed, leading
to a histopathological diagnosis of hormone receptor-
positive invasive ductal carcinoma without human epider-
mal growth factor receptor type 2 (HER2) protein overex-
pression (Fig. 3). Although the diagnostic aspiration did
not provide conclusive evidence of malignant effusion,
after reflecting on the patient’s pathological characteris-
tics, the physicians made a final diagnosis of stage IV/
metastatic breast cancer with metastases involving the
pleural cavity, peritoneal cavity, lymph nodes, and bone.
The patient began receiving tamoxifen-based hormonal
therapy because chemotherapy was deemed inappropriate
due to coexisting renal impairment. 1 month later, it
became difficult for the patient to live at home because
her massive ascites induced a bloating sensation accompa-
nied by pain, shortness of breath, a diminished appetite,
Table 2. Laboratory findings.(A) Abnormal laboratory data obtained
on admission and the changes in these parameters after chemother-
apy treatment. (B) A list of the autoantibodies associated with autoim-
mune connective tissue disorders that were tested for on admission.
On admission
After two courses
of chemotherapy
(A)
White blood cells (/lL) 3300 5300
Red blood cells (104/lL) 274 267
Hemoglobin (g/dL) 8.1 8.4
Platelets (103/lL) 115 126
Total protein (g/dL) 5.7 6.6
Albumin (g/dL) 2.7 4.0
BUN (mg/dL) 74.2 33.6
Creatinine (mg/dL) 2.2 1.5
IgG (mg/dL) 1681 1353
IgA (mg/dL) 228 171
IgM (mg/dL) 88 109
TSH (mIU/mL) 8.495 2.581
FT3 (pg/mL) 0.57 1.36
FT4 (ng/mL) 5.03 0.88
(B)
Autoimmune antibody (titer) 1:<40
Anti-DNA antibody (IU/mL) <2.0
Lupus-anticoagulant (sec) 1.0
Anticardiolipin antibody (U/mL) <1.2
Anti-RNP antibody not detected
Anti-Sm antibody not detected
Anti-SS-A antibody not detected
p-ANCA (U/mL) <1.0
c-ANCA (U/mL) <1.0
Anti-TPO antibody (IU/mL) 8.0
BUN: blood urea nitrogen, TSH: thyroid-stimulating hormone, FT3:
free triiodothyronine, FT4: free thyroxine, RNP: ribonucleoprotein,
SS-A: Sj€ogren’s syndrome-related antigen A, ANCA: antineutrophil
cytoplasmic antibodies, TPO: thyroid peroxidase.
[Correction added on 21 March 2016 after first online publication:
The units in tables 2 and 3 were incorrect and have been updated in
this version]
Table 1. The criteria for POEMS syndrome.
Major criteria
(both required)
1. Polyneuropathy (typically demyelinating)
2. Monoclonal gammopathy
Other major
criteria (1 required)
3. Castleman’s disease
4. Sclerotic bone lesions
5. Elevated VEGF levels
Minor criteria
(1 required)
6. Organomegaly (splenomegaly,
hepatomegaly, or lymphadenopathy)
7. Extravascular volume overload (edema,
pleural effusion, or ascites)
8. Endocrinopathy
9. Skin changes (e.g., hyperpigmentation,
hemangioma, etc.)
10. Papilledema
11. Thrombocytosis or polycythemia
Other symptoms
and signs
Clubbing, weight loss, hyperhidrosis,
pulmonary hypertension/restrictive lung
disease, thrombotic diatheses, diarrhea, low
vitamin B12 values
VEGF: vascular epithelial growth factor.
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nausea, severe fatigue, and edema of the lower extremi-
ties. Therefore, she was admitted to our surgical ward in
order to undergo peritoneal port-catheter placement to
manage her refractory ascites.
Differential diagnosis, examinations,
and treatment
The surgeon who performed the physical examination on
admission (the lead author of this article) noted that the
patient had several characteristic physical findings: club-
bing and hyperpigmentation of the fingers (Fig. 4A); skin
hyperpigmentation on her back together with angiomas
(Fig. 4B); and polyneuropathy, for example, numbness in
both fingers, an inability to sense vibrations in both
upper extremities, muscle weakness, and diminished deep
tendon reflexes. The detection of these characteristic
physical findings triggered a fundamental review of the
previous diagnosis, which required us to reexamine
whether the patient’s breast cancer had played a causal
role in the development of her pleural effusion, ascites,
axillary lymphadenopathy, and sclerotic bone lesions.
When we considered all of the patient’s findings (other
than the breast cancer) in a comprehensive manner, the
differential diagnoses were divided into the following
three categories: [1] hematological disorders, such as mul-
tiple myeloma, POEMS syndrome, monoclonal gam-
mopathy of undetermined significance, Waldenstrom’s
macroglobulinemia, cryoglobulinemia, and amyloidosis;
[2] immune-mediated peripheral neuropathies, such as
chronic inflammatory demyelinating polyneuropathy; and
[3] autoimmune connective tissue disorders, such as
scleroderma. However, autoimmune connective tissue dis-
orders had already been ruled out, as mentioned above.
On the other hand, the patient’s physical findings; that is,
the skin and neurological manifestations, represented
valuable clues and led to an in-depth examination for
POEMS syndrome.
To examine whether the patient met the major criteria
for POEMS syndrome (Table 1), we performed an iliac
crest bone marrow biopsy, a test for M-protein, and a
nerve conduction velocity (NCV) test. The bone marrow
biopsy showed normal cellularity and did not detect any
bone marrow plasma cell involvement, which excluded
multiple myeloma. However, IgG-k monoclonal gam-
mopathy was detected (Fig. 5), and the NCV test demon-
strated both demyelination and axonopathy in the right
upper extremities (Table 4), which were considered to be
(A)
(C)
(B)
Figure 1. CT scan obtained on admission. The scan showed (A). bilateral axillary lymph node enlargement (white arrows), (B). a large amount of
ascites, and (C). a bone sclerotic lesion in the pubic symphysis (white arrow).
Table 3. Laboratory chemical analysis of the patient’s ascites. The
results indicated that the ascites was transudative, but not malignant.
Gradient 1.024
Rivalta reaction negative
Protein (g/dL) 3.3
Albumin (g/dL) 1.8
Glucose (mg/dL) 111
Lactate dehydrogenase (U/L) 55
Total cell count (/lL) 496
Mononuclear cells (/lL) 487
Polynuclear cells (/lL) 9
[Correction added on 21 March 2016 after first online publication:
The units in tables 2 and 3 were incorrect and have been updated in
this version]
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comorbidities of the patient’s peripheral polyneuropathy.
Thereby, the diagnostic criteria for POEMS syndrome
were fulfilled because one element of the other three
major criteria (sclerotic bone lesions) and three of the
minor criteria (lymphadenopathy, extravascular volume
overloading, and skin changes) had already been met. In
addition, we obtained further strong evidence to support
this diagnosis; that is, a markedly raised VEGF level; the
patient’s plasma and serum VEGF levels were 555 pg/mL
and 1530 pg/mL, respectively. It has been reported that a
plasma VEGF level of 200 pg/mL exhibits 95% specificity
and 68% sensitivity for diagnosing POEMS syndrome [3].
According to the Japanese diagnostic criteria for POEMS
syndrome issued by the Japan Intractable Diseases Infor-
mation Center, a significantly elevated VEGF level is
defined as a serum level of >1000 ng/mL [4]. Therefore,
(A)
(B)
Figure 2. Imaging studies of the right breast. (A). A right-sided mammography showed a cluster of pleomorphic microcalcifications (white
arrows). (B). A breast ultrasound detected a hypoechoic solid tumor (size: ~1 cm) containing internal echogenic spots with interruption of both
anterior and posterior border of the mammary gland (white arrows).
HE ER
PgR HER2
Figure 3. Histopathological examinations of the right breast An ultrasound-guided needle biopsy detected hormone receptor-positive invasive
ductal carcinoma without human epidermal growth factor receptor type 2 (HER2) protein overexpression. HE: hematoxylin-eosin, ER: estrogen
receptor, PgR: progesterone receptor
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we were able to make a definitive diagnosis of POEMS
syndrome in this rare case, which also involved syn-
chronous breast cancer.
Immediately after the final diagnosis, the patient began
receiving chemotherapy based on a regimen for multiple
myeloma (1.3 mg/m2 bortezomib, SC, on days 1, 8, 22,
and 29 of each cycle and 20 mg dexamethasone, PO, on
days 1, 2, 8, 9, 22, 23, 29, and 30 of each cycle; each cycle
lasted 6 weeks) [5] as her condition was becoming
increasingly life-threatening.
Outcomes and follow-up
After two courses of chemotherapy, the patient’s pleural
effusion and ascites had almost disappeared, and her
plasma and serum VEGF levels fell significantly to 47 pg/
mL and 266 pg/mL, respectively; that is, below the diag-
nostic cut-off values of 200 pg/mL and 1000 pg/mL,
respectively, indicating that these symptoms had been
caused not by cancerous dissemination, but by POEMS
syndrome. With the decreasing extravascular volume
overload, her circulating plasma volume increased, leading
to an improvement in her kidney function (see
Table 2A), for example, her estimated glomerular filtra-
tion rate improved from 18 mL/min to 28 mL/min. Thus,
the patient’s condition had improved markedly, and she
was well enough to undergo a radical operation for breast
cancer under general anesthesia.
The patient underwent total mastectomy and complete
axillary node dissection for right breast cancer. A
histopathological examination of the resected specimens
detected a 10 9 5 mm-sized invasive ductal carcinoma
with no lymph node involvement (0/19). When investi-
gating the dissected axillary lymph nodes for POEMS syn-
drome, none of the following histopathological features of
Castleman’s disease were detected: hyaline vascular, plas-
macytic, or mixed lymph node features. Her breast cancer
subtype was diagnosed as luminal A [6]. Accordingly,
adjuvant endocrine therapy (5 years’ tamoxifen treat-
ment) was considered sufficient.
(A) (B)
Figure 4. Skin changes (A). Finger clubbing with hyperpigmentation (B) Hyperpigmentation of the back with angiomas
Figure 5. Immunoelectrophoresis The patient exhibited monoclonal gammopathy of IgG-k (red arrows).
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After receiving several more cycles of the same
chemotherapy regimen, the patient is scheduled to receive
an autologous stem cell transplant in the near future,
which is expected to result in a substantial improvement
in her neuropathy [7] [8].
Discussion
POEMS syndrome was first reported by Crow in 1956 [9]
and was subsequently described by Fukase in 1969 [10].
The acronym POEMS was coined by Bardwick in 1980
[11] and stands for the five main features of the disease;
that is, polyneuropathy, organomegaly, endocrinopathy,
monoclonal gammopathy, and skin changes. The syn-
drome was also referred to as Crow–Fukase syndrome by
Nakanishi in 1984 based on a Japanese study of 102 cases
[12], and this name is more widely known in Japan than
POEMS syndrome.
Although the pathophysiology of POEMS syndrome
is poorly understood, the production of various inflam-
matory cytokines, such as interleukins (IL-1 and IL-6)
and VEGF, by abnormal plasma cells is postulated to
play a direct causal role in various symptoms of the
condition [13, 14]. In particular, VEGF levels exhibit
the strongest correlations with disease activity in
POEMS syndrome [3,15]. Plasma and serum VEGF
levels of 200 pg/mL and 1,000 pg/mL, respectively, are
considered to be diagnostic cut-off values for POEMS
syndrome. Elevated VEGF levels are postulated to be
involved in the pathogenesis of enhanced vascular
permeability, increased endoneurial pressure, and the
deposition of plasma cell-derived material [14, 16, 17],
which eventually cause a variety of symptoms, including
extravascular volume overloading (edema, pleural effu-
sion, and/or ascites), polyneuropathy (demyelination),
sclerotic bone lesions, and skin changes [18, 19].
However, the mixed results seen with anti-VEGF ther-
apy indicate that VEGF might not be the driver of the
clinical manifestations of POEMS syndrome [20]. Fur-
ther studies of this issue are required.
To the best of our knowledge (based on a search of the
PubMed database), this is the first case report about a
case of POEMS syndrome with synchronous breast can-
cer. Using “POEMS syndrome” and “synchronous cancer”
as search keywords, we did not find any relevant articles
(accessed Oct 19, 2015). At present, there is no evidence
that certain types of cancer are strongly associated with
POEMS syndrome. Thus, it is likely that the current
patient developed POEMS syndrome and breast cancer
synchronously by chance.
The following three major factors might help to
explain the diagnostic difficulties encountered in the pre-
sent case. First, POEMS syndrome is a rare disease; its
prevalence rate was reported to be 0.3 per 100,000 in
Japan [17]. However, there is another fact that some
patients with POEMS syndrome are first diagnosed at
autopsy or go undiagnosed unless properly autopsied
because of diagnostic challenges specific to the syndrome
[21], which makes the actual prevalence rate unclear. Sec-
ond, many of the signs and symptoms of POEMS syn-
drome mimic those of other disorders, leading to
confusion and difficulties during the diagnostic process.
Especially when being diagnosed with a certain type of
cancer before the detection of preexisting POEMS syn-
drome, pleural effusion, ascites, lymphadenopathy, and
bone lesions might be considered to be carcinomatous in
origin. The risk of such mistakes is probably higher in
cases involving a metastasis-prone cancer, for example,
breast cancer. Third, clinicians have recently appeared to
rely excessively on laboratory findings and/or imaging
studies during the diagnostic process. This trend down-
plays the significance of physical examinations. The pre-
sent case should act as a warning against this unfavorable
trend and could yield a bitter but helpful lesson that,
“the more complex a disease is, the more important a
physical examination tends to be”.
Table 4. A NCV study of the patient’s right side.
Distal latency (msec) Amplitude (mV) NCV (m/sec)
Median motor 7.35 (3.0–3.8) 7.01 (5.3–11.1) 28.5 (53.8–61.4)
sensory unmeasurable
Ulnar motor 6.75 (3.3–2.9) 4.28 (5.6–9.2) 34.0 (53.4–62.6)
sensory 22.0 (13.5–34.1) 33.7 (51.0–61.6)
Tibial motor unmeasurable
Peroneal motor unmeasurable
Sural sensory unmeasurable
NCV, nerve conduction velocity.
As a reference, normal values are shown in parentheses. [22] This test detected mixed neuropathy in the median motor nerve and ulnar motor
nerve (a long latency, low amplitude, and low NCV), and axonal neuropathy in the right ulnar sensory nerve (a low NCV). The NCV of the median
sensory nerve, tibial motor nerve, peroneal motor nerve, and sural sensory nerve were unmeasurable.
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